But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

Here, we explain the facts behind several more of Robert F. Kennedy Jr.’s claims during his two Senate hearings as nominee ...

Employers are offering services from vendors such as HealthJoy, Healthee and Transcarent to help workers navigate ...

Tuesday is World Cancer Day, and one volunteer has spent decades raising funds. One Erie resident is teaming up with the ...

Gov. Ned Lamont eyed Medicaid reimbursement rates, a hospital tax restructuring and pharmaceutical costs in his biennial ...

For anyone who is tired of relentless vehicle size inflation (and the terrible effect they have on road space and road safety ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Novo Nordisk has achieved another blockbuster financial year as the group cheered intense global demand for its obesity and diabetes ... take out a product This is Money may earn a commission.

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

Jan. 27, 2025 — A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future ... Signposting Children to ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.